Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

8233 ARTÍCULOS , VIENDO DEL 556 AL 570

Microglial TLR4/NLRP3 Inflammasome Signaling in Alzheimer's Disease

Li Y, Chen X, Zhou M, Feng S, Peng X, Wang Y.

J Alzheimers Dis. 2024;97(1):75-88. doi: 10.3233/JAD-230273.

Sulfopropanoic acid derivatives for treating neurodegenerative disorders: a patent spotlight

Al-Horani RA.

Pharm Pat Anal. 2024;13(4-6):131-137. doi: 10.1080/20468954.2024.2363657. Epub 2024 Jun 20.

Oxidative stress in Alzheimer's disease: current knowledge of signaling pathways and therapeutics

Dhapola R, Beura SK, Sharma P, Singh SK, HariKrishnaReddy D.

Mol Biol Rep. 2024 Jan 2;51(1):48. doi: 10.1007/s11033-023-09021-z.

Novel avenues of tau research

Sexton CE, Bitan G, Bowles KR, Brys M, Buée L, Maina MB, Clelland CD, Cohen AD, Crary JF, Dage JL, Diaz K, Frost B, Gan L, Goate AM, Golbe LI, Hansson O, Karch CM, Kolb HC, La Joie R, Lee SE, Matallana D, Miller BL, Onyike CU, Quiroz YT, Rexach JE, Rohrer JD, Rommel A, Sadri-Vakili G, Schindler SE, Schneider JA, Sperling RA, Teunissen CE, Weninger SC, Worley SL, Zheng H, Carrillo MC.

Alzheimers Dement. 2024 Mar;20(3):2240-2261. doi: 10.1002/alz.13533. Epub 2024 Jan 3.

Therapeutic Effects of the major alkaloid constituents of Evodia rutaecarpa in Alzheimer's disease

Cao Q, Dong P, Han H.

Psychogeriatrics. 2024 Mar;24(2):443-457. doi: 10.1111/psyg.13051. Epub 2024 Jan 3.

Report of the APOE4 National Institute on Aging/Alzheimer Disease Sequencing Project Consortium Working Group: Reducing APOE4 in Carriers is a Therapeutic Goal for Alzheimer's Disease

Vance JM, Farrer LA, Huang Y, Cruchaga C, Hyman BT, Pericak-Vance MA, Goate AM, Greicius MD, Griswold AJ, Haines JL, Tcw J, Schellenberg GD, Tsai LH, Herz J, Holtzman DM.

Ann Neurol. 2024 Apr;95(4):625-634. doi: 10.1002/ana.26864. Epub 2024 Jan 5.

The function of sphingolipids in different pathogenesis of Alzheimer's disease: A comprehensive review

Wang X, Li H, Sheng Y, He B, Liu Z, Li W, Yu S, Wang J, Zhang Y, Chen J, Qin L, Meng X.

Biomed Pharmacother. 2024 Feb;171:116071. doi: 10.1016/j.biopha.2023.116071. Epub 2024 Jan 6.

How promising are the latest monoclonal antibodies targeting amyloid-β for the treatment of early Alzheimer's disease?

Beveridge J, Kaniecki E, Naidu A, Silverglate BD, Grossberg G.

Expert Opin Emerg Drugs. 2024 Mar;29(1):35-43. doi: 10.1080/14728214.2024.2304059. Epub 2024 Jan 12.

Agents at the Peak of US FDA Approval for the Treatment of Alzheimer's Disease

Alam J, Kalash A, Hassan MI, Rahman SZ.

Neurol Res. 2024 Apr;46(4):318-325. doi: 10.1080/01616412.2024.2302271. Epub 2024 Jan 10.

Multi-Target-Directed Cinnamic Acid Hybrids Targeting Alzheimer's Disease

Drakontaeidi A, Pontiki E.

Int J Mol Sci. 2024 Jan 1;25(1):582. doi: 10.3390/ijms25010582.

Potential links between platelets and amyloid-β in the pathogenesis of Alzheimer's disease: Evidence from in vitro, in vivo, and clinical studies

Yubolphan R, Pratchayasakul W, Koonrungsesomboon N, Chattipakorn N, Chattipakorn SC.

Exp Neurol. 2024 Apr;374:114683. doi: 10.1016/j.expneurol.2024.114683. Epub 2024 Jan 9.

Passive immunotherapy for Alzheimer's disease

Guo X, Yan L, Zhang D, Zhao Y.

Ageing Res Rev. 2024 Feb;94:102192. doi: 10.1016/j.arr.2024.102192. Epub 2024 Jan 14.

Antioxidant, anti-inflammatory and epigenetic potential of curcumin in Alzheimer's disease

Abdul-Rahman T, Awuah WA, Mikhailova T, Kalmanovich J, Mehta A, Ng JC, Coghlan MA, Zivcevska M, Tedeschi AJ, de Oliveira EC, Kumar A, Cantu-Herrera E, Lyndin M, Sikora K, Alexiou A, Bilgrami AL, Al-Ghamdi KM, Perveen A, Papadakis M, Ashraf GM.

Biofactors. 2024 Jul-Aug;50(4):693-708. doi: 10.1002/biof.2039. Epub 2024 Jan 16.

Alzheimer's disease, aging, and cannabidiol treatment: a promising path to promote brain health and delay aging

Liu Y.

Mol Biol Rep. 2024 Jan 16;51(1):121. doi: 10.1007/s11033-023-09162-1.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias